Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy

医学 荟萃分析 置信区间 掌跖脓疱病 随机对照试验 优势比 梅德林 分级(工程) 系统回顾 随机效应模型 内科学 物理疗法 皮肤病科 银屑病 工程类 土木工程 政治学 法学
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:38 (2): 281-288 被引量:5
标识
DOI:10.1111/jdv.19499
摘要

Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta-analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random-effects model was accepted to perform network meta-analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI-50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], -8.00; 95% confidence interval [CI], 4.88-11.11), while the achievement of PPPASI-50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51-28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, -4.71; 95% CI, 2.12-7.30), while the achievement of PPPASI-50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48-11.43). Network meta-analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI-50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI-50.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
曦_完成签到,获得积分10
2秒前
jin发布了新的文献求助10
2秒前
ST关闭了ST文献求助
6秒前
张航完成签到,获得积分10
7秒前
邬佑鑫发布了新的文献求助10
7秒前
丘比特应助liyuanyuan采纳,获得10
8秒前
路星辞完成签到 ,获得积分10
9秒前
华仔应助热情的如雪采纳,获得10
9秒前
小Z发布了新的文献求助10
9秒前
昀丶完成签到,获得积分10
10秒前
金牌小魚仔应助treasure盼采纳,获得10
12秒前
14秒前
77完成签到,获得积分10
14秒前
14秒前
普通人生完成签到,获得积分10
14秒前
李健的小迷弟应助YangHH采纳,获得10
15秒前
15秒前
慕青应助ddd采纳,获得10
16秒前
Otto Curious发布了新的文献求助10
16秒前
瓶盖发布了新的文献求助10
18秒前
19秒前
20秒前
20秒前
路人发布了新的文献求助10
21秒前
22秒前
CodeCraft应助邬佑鑫采纳,获得10
22秒前
cdercder应助快乐友灵采纳,获得10
22秒前
24秒前
领导范儿应助超帅雨旋采纳,获得10
24秒前
xwy完成签到,获得积分10
24秒前
精明元霜应助天思采纳,获得20
26秒前
Jasper应助icelatte采纳,获得10
27秒前
Otto Curious完成签到,获得积分10
27秒前
28秒前
糊里糊涂发布了新的文献求助10
28秒前
江子川发布了新的文献求助20
28秒前
29秒前
金平一小完成签到,获得积分10
29秒前
高分求助中
Markov Chain Monte Carlo 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Common Foundations of American and East Asian Modernisation: From Alexander Hamilton to Junichero Koizumi 5000
悉尼大学博士学位论文,题目:Modelling and testing of one-sided stitched laminated composites. 作者:Kristopher P. Plain 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
Blackwell's five-minute veterinary consult clinical companion: small animal gastrointestinal diseases 500
Data book on fatigue strength of metallic materials 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7562841
求助须知:如何正确求助?哪些是违规求助? 9143566
关于积分的说明 19549470
捐赠科研通 7150686
什么是DOI,文献DOI怎么找? 3262335
关于科研通互助平台的介绍 2428586
邀请新用户注册赠送积分活动 2251853